Literature DB >> 4008608

Gastric inhibitory polypeptide responses to nutrients in Caucasians and American Indians with obesity and noninsulin-dependent diabetes mellitus.

E L Mazzaferri, G H Starich, C K Lardinois, G D Bowen.   

Abstract

Serum gastric inhibitory polypeptide (GIP), insulin, and glucose responses to either a 75-g oral glucose challenge or a 500-cal liquid test meal were determined in 141 Caucasians and American Indians. The Caucasians were normal weight, averaging 101 +/- 3% (+/-SEM) ideal BW (IBW), or were obese (168 +/- 21% IBW) and had normal glucose tolerance (n = 77), impaired glucose tolerance (IGT; n = 12), or noninsulin-dependent diabetes mellitus (NIDDM; n = 19). The American Indians were all obese (144 +/- 6% IBW) and had either normal glucose tolerance (n = 22) or NIDDM (n = 11). In all study subjects, including obese individuals with and without glucose intolerance, diabetic patients both thin and obese, and lean subjects with impaired glucose tolerance, fasting serum insulin and GIP, and incremental glucose, insulin, and GIP were greater than they were in normal lean subjects, especially during the first hour of the tests. Obese subjects and diabetic patients exceeded lean normal subjects by up to 620% for glucose, up to 640% for insulin, and up to 360% for GIP during the first hour after glucose ingestion or the test meal. Exceptions were two groups with the most severe diabetes in whom incremental insulin values after oral glucose were only 70% (thin Caucasians) and 110% (obese Indians) that of lean normal subjects. The smallest differences in GIP responses occurred between lean normal subjects and obese nondiabetic Caucasians tested with either a meal or oral glucose, whereas American Indians consistently had the greatest insulin and GIP responses to the tests. High fasting GIP and exaggerated GIP increments in response to nutrients could be attributed to neither obesity nor diabetes alone nor to the type of nutrient used to stimulate its release, but, instead, may be genetic or dietary in origin or may be due to other as yet unidentified factors. High basal GIP and exaggerated nutrient-stimulated GIP release were associated with hyperinsulinemia, except in the most severe diabetic patients. These observations suggest that exaggerated GIP release, along with a greater rise in serum glucose in response to nutrients, may play a role in the pathogenesis of the hyperinsulinemia of obesity and early NIDDM.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4008608     DOI: 10.1210/jcem-61-2-313

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial.

Authors:  Özlem Gögebakan; Martin A Osterhoff; Rita Schüler; Olga Pivovarova; Michael Kruse; Anne-Cathrin Seltmann; Alexander S Mosig; Natalia Rudovich; Michael Nauck; Andreas F H Pfeiffer
Journal:  Diabetologia       Date:  2015-05-21       Impact factor: 10.122

2.  Prebiotic fiber increases hepatic acetyl CoA carboxylase phosphorylation and suppresses glucose-dependent insulinotropic polypeptide secretion more effectively when used with metformin in obese rats.

Authors:  Kim A Pyra; Dolan C Saha; Raylene A Reimer
Journal:  J Nutr       Date:  2012-01-05       Impact factor: 4.798

3.  Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia.

Authors:  R Ebert; W Creutzfeldt
Journal:  Acta Diabetol Lat       Date:  1989 Jan-Mar

4.  Postnatal prebiotic fibre intake mitigates some detrimental metabolic outcomes of early overnutrition in rats.

Authors:  Danielle T Reid; Lindsay K Eller; Jodi E Nettleton; Raylene A Reimer
Journal:  Eur J Nutr       Date:  2015-09-25       Impact factor: 5.614

Review 5.  Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.

Authors:  Salvatore Calanna; Mikkel Christensen; Jens J Holst; Blandine Laferrère; Lise L Gluud; Tina Vilsbøll; Filip K Knop
Journal:  Diabetes Care       Date:  2013-10       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.